Aim/Introduction: triple-negative breast cancer (TNBC) is an aggressive malignancy, and its management remains challenging due to limited therapeutic options. As such, accurate diagnosis is crucial to ensure timely and effective treatment decisions. TNBC is known to be an [18F]-FDG-avid tumor; however, [18F]-FDG PET/ CT is still employed in only a limited number of clinical scenarios. TRINE-PET is a large, retrospective, real-world multicenter Italian study designed to investigate the correlation between [18F]-FDG PET/CT findings and survival outcomes in TNBC patients across different clinical stages of the disease. This sub-analysis of the TRINEPET study aims to assess the clinical impact of [18F]-FDG PET/CT in influencing the changes in patient therapeutic management. Materials and Methods: data on [18F]-FDG PET/CT in TNBC patients were retrospectively collected from 24 Italian centers. Scans were categorized into four clinical settings: (a) baseline, (b) post-neoadjuvant chemotherapy (NAC), (c) suspected disease recurrence, and (d) patients undergoing systemic therapies. For inclusion, a minimum follow-up of two years was required. Clinical decisions made following [18F]-FDG PET/CT were recorded, and the percentage of changes in patient therapeutic management was calculated for each clinical setting. Results: a total of 707 [18F]-FDG PET/CT scans from 389 patients (mean age = 54 ± 13 years) were analyzed. The distribution of scans across clinical settings was as follows: baseline = 257, post-NAC = 111, suspected recurrence = 144, and systemic therapy = 195. [18F]-FDG PET/CT led to a change in therapeutic management in 22 (8.6%) baseline cases, 15 (13.5%) post-NAC cases, 42 (29.2%) cases with suspected recurrence, and 68 (35%) cases in patients receiving systemic therapies. Conclusion: the clinical impact of [18F]-FDG PET/CT in guiding treatment decisions increased with the progression of the stages of disease. A lower influence on patients therapeutic management was observed when PET/CT was performed at baseline or after NAC. In contrast, [18F]-FDG PET/CT significantly influenced therapeutic decisions in patients with suspected recurrence and in those undergoing systemic therapy. R
The impact of [18F]FDG PET/CT in guiding the change of management of triple-negative breast cancer patients: a sub-analysis of the TRINE-PET trial / Urso, L.; Panareo, S.; Iudicello, A.; Albano, D.; Calcagni, M. L.; Mazzoletti, A.; Sciuto, R.; Fantini, L.; Rovera, G.; Sofia, L.; Guglielmo, P.; Sorbello, S.; Bambaci, M.; Ialuna, S.; Miceli, A.; Rizza, E.; Ferrari, C.; Marongiu, A.; Garrou, F.; Bertin, D.; Arnone, A.; Colombo, C.; Maffione, A. M.; Donner, D.; Evangelista25, L.. - (2025).
The impact of [18F]FDG PET/CT in guiding the change of management of triple-negative breast cancer patients: a sub-analysis of the TRINE-PET trial
A. Marongiu;
2025-01-01
Abstract
Aim/Introduction: triple-negative breast cancer (TNBC) is an aggressive malignancy, and its management remains challenging due to limited therapeutic options. As such, accurate diagnosis is crucial to ensure timely and effective treatment decisions. TNBC is known to be an [18F]-FDG-avid tumor; however, [18F]-FDG PET/ CT is still employed in only a limited number of clinical scenarios. TRINE-PET is a large, retrospective, real-world multicenter Italian study designed to investigate the correlation between [18F]-FDG PET/CT findings and survival outcomes in TNBC patients across different clinical stages of the disease. This sub-analysis of the TRINEPET study aims to assess the clinical impact of [18F]-FDG PET/CT in influencing the changes in patient therapeutic management. Materials and Methods: data on [18F]-FDG PET/CT in TNBC patients were retrospectively collected from 24 Italian centers. Scans were categorized into four clinical settings: (a) baseline, (b) post-neoadjuvant chemotherapy (NAC), (c) suspected disease recurrence, and (d) patients undergoing systemic therapies. For inclusion, a minimum follow-up of two years was required. Clinical decisions made following [18F]-FDG PET/CT were recorded, and the percentage of changes in patient therapeutic management was calculated for each clinical setting. Results: a total of 707 [18F]-FDG PET/CT scans from 389 patients (mean age = 54 ± 13 years) were analyzed. The distribution of scans across clinical settings was as follows: baseline = 257, post-NAC = 111, suspected recurrence = 144, and systemic therapy = 195. [18F]-FDG PET/CT led to a change in therapeutic management in 22 (8.6%) baseline cases, 15 (13.5%) post-NAC cases, 42 (29.2%) cases with suspected recurrence, and 68 (35%) cases in patients receiving systemic therapies. Conclusion: the clinical impact of [18F]-FDG PET/CT in guiding treatment decisions increased with the progression of the stages of disease. A lower influence on patients therapeutic management was observed when PET/CT was performed at baseline or after NAC. In contrast, [18F]-FDG PET/CT significantly influenced therapeutic decisions in patients with suspected recurrence and in those undergoing systemic therapy. RI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
